tiprankstipranks
Trending News
More News >

Coya Therapeutics Reports Q1 2025 Financial Results

Story Highlights
Coya Therapeutics Reports Q1 2025 Financial Results

Don’t Miss TipRanks’ Half-Year Sale

Coya Therapeutics, Inc. ( (COYA) ) has provided an update.

Coya Therapeutics reported its first-quarter financial results for 2025, highlighting significant advancements in its clinical programs. The company announced positive interim results from a study on Frontotemporal Dementia and progress in its Treg-derived exosome program. Coya also detailed improvements in inflammatory markers in Alzheimer’s patients and expanded its pipeline with COYA 303 and COYA 301. Financially, Coya reported a net loss of $7.3 million for the quarter, with increased R&D expenses driven by preclinical advancements.

The most recent analyst rating on (COYA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Coya Therapeutics, Inc. stock, see the COYA Stock Forecast page.

Spark’s Take on COYA Stock

According to Spark, TipRanks’ AI Analyst, COYA is a Neutral.

Coya Therapeutics, Inc. has a mixed outlook. Strong clinical progress and financial stability from a debt-free balance sheet with cash reserves are significant positives. However, persistent profitability and cash flow challenges weigh heavily on the overall score. Technical indicators suggest moderate momentum, while valuation remains pressured by ongoing losses. The company’s strategic advancements and funding efforts are positive but need to translate into improved financial performance to enhance the stock’s appeal.

To see Spark’s full report on COYA stock, click here.

More about Coya Therapeutics, Inc.

Coya Therapeutics, Inc., based in Houston, TX, is a clinical-stage biotechnology company focused on developing treatments that leverage the biology of regulatory T cells (Tregs) to address systemic inflammation and neuroinflammation. The company’s pipeline includes Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy aimed at treating neurodegenerative, metabolic, and autoimmune diseases.

Average Trading Volume: 95,315

Technical Sentiment Signal: Sell

See more data about COYA stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1